74 related articles for article (PubMed ID: 21790004)
1. [Melanoma: surface markers as the first point of targeted delivery of therapeutic genes in multilevel gene therapy].
Pleshkan VV; Zinov'eva MV; Sverdlov ED
Mol Biol (Mosk); 2011; 45(3):416-33. PubMed ID: 21790004
[TBL] [Abstract][Full Text] [Related]
2. Cytolytic T-cell clones define HLA-A2-restricted human cutaneous melanoma peptide epitopes: correlation with T-cell receptor usage.
Maeurer MJ; Hurd S; Martin DM; Storkus WJ; Lotze MT
Cancer J Sci Am; 1995; 1(2):162-70. PubMed ID: 9166469
[TBL] [Abstract][Full Text] [Related]
3. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.
Corbière V; Chapiro J; Stroobant V; Ma W; Lurquin C; Lethé B; van Baren N; Van den Eynde BJ; Boon T; Coulie PG
Cancer Res; 2011 Feb; 71(4):1253-62. PubMed ID: 21216894
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation.
Wankowicz-Kalinska A; Mailliard RB; Olson K; Graham F; Edington H; Kirkwood JM; Martinek S; Das PK; Storkus WJ
Melanoma Res; 2006 Apr; 16(2):165-74. PubMed ID: 16567972
[TBL] [Abstract][Full Text] [Related]
5. Immunology and immunotherapy of human malignant melanoma.
Bystryn JC
Dermatol Clin; 1985 Apr; 3(2):327-34. PubMed ID: 2937585
[TBL] [Abstract][Full Text] [Related]
6. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
7. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
8. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
[TBL] [Abstract][Full Text] [Related]
9. [Tumor antigens recognized by T-lymphocytes in human cancers. New advances and therapeutic perspectives].
Gaugler B; Olive D
Pathol Biol (Paris); 1998 Dec; 46(10):771-8. PubMed ID: 9922993
[TBL] [Abstract][Full Text] [Related]
10. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
[TBL] [Abstract][Full Text] [Related]
11. Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells.
Fukushima S; Hirata S; Motomura Y; Fukuma D; Matsunaga Y; Ikuta Y; Ikeda T; Kageshita T; Ihn H; Nishimura Y; Senju S
J Immunother; 2009 Apr; 32(3):219-31. PubMed ID: 19242378
[TBL] [Abstract][Full Text] [Related]
12. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
13. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro.
Bakker AB; Marland G; de Boer AJ; Huijbens RJ; Danen EH; Adema GJ; Figdor CG
Cancer Res; 1995 Nov; 55(22):5330-4. PubMed ID: 7585596
[TBL] [Abstract][Full Text] [Related]
14. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene.
Chiari R; Foury F; De Plaen E; Baurain JF; Thonnard J; Coulie PG
Cancer Res; 1999 Nov; 59(22):5785-92. PubMed ID: 10582700
[TBL] [Abstract][Full Text] [Related]
15. Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy.
López MN; Pereda C; Ramírez M; Mendoza-Naranjo A; Serrano A; Ferreira A; Poblete R; Kalergis AM; Kiessling R; Salazar-Onfray F
Invest Ophthalmol Vis Sci; 2007 Mar; 48(3):1219-27. PubMed ID: 17325166
[TBL] [Abstract][Full Text] [Related]
16. [A malignus melanoma immunterápiájának lehetoségei].
Ladányi A
Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
[TBL] [Abstract][Full Text] [Related]
17. The perforin-dependent immunological synapse allows T-cell activation-dependent tumor targeting by MLV vector particles.
Kottke T; Qiao J; Diaz RM; Ahmed A; Vroman B; Thompson J; Sanchez-Perez L; Vile R
Gene Ther; 2006 Aug; 13(15):1166-77. PubMed ID: 16625245
[TBL] [Abstract][Full Text] [Related]
18. Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis.
Leslie MC; Zhao YJ; Lachman LB; Hwu P; Wu GJ; Bar-Eli M
Gene Ther; 2007 Feb; 14(4):316-23. PubMed ID: 17024104
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus targeting to HLA-A1/MAGE-A1-positive tumor cells by fusing a single-chain T-cell receptor with minor capsid protein IX.
de Vrij J; Uil TG; van den Hengel SK; Cramer SJ; Koppers-Lalic D; Verweij MC; Wiertz EJ; Vellinga J; Willemsen RA; Hoeben RC
Gene Ther; 2008 Jul; 15(13):978-89. PubMed ID: 18323790
[TBL] [Abstract][Full Text] [Related]
20. A novel DNA vaccine based on ubiquitin-proteasome pathway targeting 'self'-antigens expressed in melanoma/melanocyte.
Zhang M; Obata C; Hisaeda H; Ishii K; Murata S; Chiba T; Tanaka K; Li Y; Furue M; Chou B; Imai T; Duan X; Himeno K
Gene Ther; 2005 Jul; 12(13):1049-57. PubMed ID: 15800663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
